Synopsis
Synopsis
0
CEP/COS
0
NDC API
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(2-tetrahydrofuryl)-5-fluorouracil
2. 1-(tetrahydro-2-furanyl)-5-fluorouracil
3. 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
4. Florafur
5. Fluorofur
6. Ft 207
7. Ft-207
8. Ft207
9. Ftorafur
10. Futraful
11. N1-(2'-tetrahydrofuryl)-5-fluorouracil
12. Sunfural S
13. Uftoral
14. Utefos
1. Ftorafur
2. 17902-23-7
3. Futraful
4. Sinoflurol
5. Fental
6. Fluorofur
7. Citofur
8. Neberk
9. Coparogin
10. Furafluor
11. Furofutran
12. Nitobanil
13. Exonal
14. Fulfeel
15. Lifril
16. Lamar
17. Tefsiel C
18. Florafur
19. Riol
20. 5-fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
21. Ft-207
22. Franroze
23. Furflucil
24. Sunfral
25. 1-(2-tetrahydrofuryl)-5-fluorouracil
26. Franrose
27. Phthorafur
28. Sunfural
29. Fulaid
30. 5-fluoro-1-(tetrahydro-2-furyl)uracil
31. Mjf-12264
32. 2,4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-
33. Atillon
34. Fluorafur
35. Nsc-148958
36. 5-fluoro-1-(tetrahydro-2-furfuryl)uracil
37. Uracil, 5-fluoro-1-(tetrahydro-2-furyl)-
38. Ft 207
39. 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
40. N1-(2-tetrahydrofuryl)-5-fluorouracil
41. 1-(tetrahydrofuran-2-yl)-5-fluorouracil
42. 5-fluoro-1-(tetrahydrofuran-2-yl)uracil
43. Uracil, 1-(tetrahydrofuran-2-yl)-5-fluoro-
44. 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
45. Nsc 148958
46. 5-fluoro-1-(tetrahydro-3-furyl)uracil
47. 1-(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione
48. Mls000069497
49. Chebi:32188
50. 1-(2-tetrahydroformyl)-5-fluorouracil
51. 1548r74nsz
52. 5-fluoro-1-tetrahydrofuran-2-yl-pyrimidine-2,4-dione
53. Ncgc00159418-02
54. Ncgc00159418-05
55. Smr000059106
56. 2,4(1h,3h)pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-
57. Racemic Ftorafur
58. Dsstox_cid_1305
59. Dsstox_rid_76070
60. Dsstox_gsid_21305
61. Phthorafur [czech]
62. Ft-207 (nsc 148958)
63. Tegafurum
64. Tegafurum [inn-latin]
65. Cas-37076-68-9
66. Ccris 2762
67. Ft207
68. Einecs 241-846-2
69. Mfcd00012351
70. Brn 0525766
71. N1-(2'-tetrahydrofuryl)-5-fluorouracil
72. 1-(tetrahydro-2-furanyl)-5-fluorouracil
73. Unii-1548r74nsz
74. N(sub 1)-(2-tetrahydrofuryl)-5-fluorouracil
75. Tegafur [usan:inn:ban:jan]
76. N(sub 1)-(2'-furanidyl)-5-fluouracil [czech]
77. Atillon (tn)
78. Tegafur ,(s)
79. N(sub 1)-(2'-furanidyl)-5-fluouracil
80. Ts-1 (salt/mix)
81. Tegafur [usan]
82. Tegafur [inn]
83. Tegafur [jan]
84. Tegafur [mi]
85. Opera_id_1726
86. Tegafur [mart.]
87. Tegafur [who-dd]
88. Upcmld-dp063
89. Schembl4552
90. Tegafur [ema Epar]
91. 5-24-06-00285 (beilstein Handbook Reference)
92. 79107-97-4
93. Mls000759414
94. Mls001076521
95. Mls001424119
96. Chembl20883
97. Tegafur (jp17/usan/inn)
98. F-5-fu
99. Teysuno Component Tegafur
100. Upcmld-dp063:001
101. Gtpl10513
102. Dtxsid001009966
103. Hms1665i05
104. Hms2051b15
105. Hms2090k04
106. Hms2232e05
107. Hms3371h21
108. Hms3393b15
109. Hms3654p13
110. Hms3715d14
111. N1-(2'-furanidyl)-5-fluouracil
112. 5-fluoro-1-(tetrahydro-2-furanyl)-2,4(1h,3h)-pyrimidinedione
113. Bcp22714
114. Tegafur Component Of Teysuno
115. 5-fluoro-1-(tetrahydrofuran-2-yl)
116. N1-(2'-furanidyl)-5-fluorouracil
117. Tox21_111649
118. Tox21_301812
119. Bbl027795
120. Ccg-50110
121. Stk528044
122. Tegafur, >=98% (hplc), Powder
123. 5-fluoro-1-(2-tetrahydrofuryl)uracil
124. Akos000121279
125. Tox21_111649_1
126. Ac-2112
127. Ccg-100959
128. Cs-1128
129. Db09256
130. Nc00209
131. 1-(tetrahydro-2-furyl)-5-fluorouracil
132. 2,4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, Didehydroderiv.
133. 5-fluoro-1-(2-tetrahydrofuranyl)uracil
134. 5-fluoro-1-(tetrahydro-2-furyl)-uracil
135. N1 -(2-tetrahydrofuryl)-5-fluorouracil
136. Ncgc00159418-04
137. Ncgc00255222-01
138. 82294-77-7
139. As-13528
140. Hy-17400
141. Tegafur (ft-207; Nsc 148958)
142. Ft-0653732
143. Ft-0654170
144. Ft-0674829
145. Ft-0693965
146. D01244
147. Ab00572620-15
148. 902t237
149. A812417
150. Q413370
151. Sr-01000639511
152. Q-201784
153. Sr-01000639511-1
154. Sr-01000639511-4
155. 5-fluoro-1-tetrahydro-furan-2-yl-1h-pyrimidine-2,4-dione
156. 5-fluoro-1-tetrahydro-2-furanyl-2,4(1h,3h)-pyrimidinedione
157. 2, 4(1h,3h)-pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-, (r)-
| Molecular Weight | 200.17 g/mol |
|---|---|
| Molecular Formula | C8H9FN2O3 |
| XLogP3 | -0.3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 200.05972032 g/mol |
| Monoisotopic Mass | 200.05972032 g/mol |
| Topological Polar Surface Area | 58.6 Ų |
| Heavy Atom Count | 14 |
| Formal Charge | 0 |
| Complexity | 316 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs. Indicated in adults for the treatment of advanced gastric cancer when given in combination with [DB00515]. Indicated for the first-line treatment of metastatic colorectal cancer with [DB03419] and calcium folinate.
Tegafur is an antineoplastic agent that belongs in the class of pyrimidine analogues. It interferes with the 2'-deoxythymidylate (DTMP) synthesis in the pyrimidine pathway, resulting in inhibition of DNA synthesis. In a phase III trial investigating the clinical efficacy of S-1 (tegafur/gimeracil/oteracil) in patients with advanced or recurrent gastric cancer, treatment resulted in a high response rate and was associated with a longer overall survival and longer progression-free survival rate when used in combination with cisplatin. In a meta analysis, triple combination therapy consisting of tegafur, gimeracil and oteracil showed longer survival times and well tolerance in patients with advanced gastric cancer. Tegafur and its active metabolites are potent myleosuppressive agents.
Antimetabolites, Antineoplastic
Antimetabolites that are useful in cancer chemotherapy. (See all compounds classified as Antimetabolites, Antineoplastic.)
L01BC53
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01B - Antimetabolites
L01BC - Pyrimidine analogues
L01BC03 - Tegafur
Absorption
Tegafur displays a dose-proportional pharmacokinetic properties. Tegafur is rapidly and well absorbed into the systemic circulation, reaching the peak plasma concentration within 1 to 2 hours of administration.
Route of Elimination
Following oral administration, about less 20% of total tegafur is excreted unchanged in the urine.
Volume of Distribution
The volume of distribution based on apparent volume of distribution and urinary excretion data of tegafur is 16 L/m^2.
Clearance
No pharmacokinetic data available.
Hepatic CYP2A6 is the predominant enzyme that mediates 5-hydroxylation of tegafur to generate 5'-hydroxytegafur. This metabolite is unstable and undergoes spontaneous degradation to form 5-FU, which is an active antineoplastic agent that exerts a pharmacological action on tumours. 5-FU is rapidly metabolised by the liver enzyme dihydropyrimidine dehydrogenase (DPD).
Tegafur has known human metabolites that include 5-Fluorouracil.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
The elimination half life of tegafur is approximately 11 hours.
The transformation of 2'-deoxyurindylate (dUMP) to 2'-deoxythymidylate (dTMP) is essential in driving the synthesis of DNA and purines in cells. Thymidylate synthase catalyzes the conversion of dUMP to dTMP, which is a precursor of thymidine triphosphate (TTP), one of the four deoxyribonucleotides required for DNA synthesis. After administration into the body, tegafur is converted into the active antineoplastic metabolite, fluorouracil (5-FU). In tumour cells, 5-FU undergoes phosphorylation to form the active anabolites, including 5-fluorodeoxyuridine monophosphate (FdUMP). FdUMP and reduced folate are bound to thymidylate synthase leading to formation of a ternary complex which inhibits DNA synthesis. In addition, 5-fluorouridine-triphosphate (FUTP) is incorporated into RNA causing disruption of RNA functions.
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
Regulatory Info :
Registration Country : Italy
Brand Name : Teysuno
Dosage Form : Tegafur+Gimeracil Oteracil+15+4,35+11,8Mg 126 Unita' Oral Use
Dosage Strength : 126 cps 15 mg + 4.35mg + 11.8 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Teysuno
Dosage Form : Tegafur+Gimeracil Oteracil+15+4,35+11,8Mg 42 Combined Oral Use
Dosage Strength : 42 cps 15 mg + 4.35mg + 11.8 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Teysuno
Dosage Form : Tegafur+Gimeracil Oteracil+20+5,8+15,8Mg 42 Combined Oral Use
Dosage Strength : 42 cps 20 mg + 5.8 mg + 15.8 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Italy
Brand Name : Teysuno
Dosage Form : Tegafur+Gimeracil Oteracil+20+5,8+15,8Mg 84 Combined Oral Use
Dosage Strength : 84 cps 20 mg + 5.8 mg + 15.8 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Teysuno
Dosage Form : Capsule, hard
Dosage Strength : 15 mg/4.35 mg/11.8 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Teysuno
Dosage Form : Capsule, hard
Dosage Strength : 15 mg/4.35 mg/11.8 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Teysuno
Dosage Form : Capsule, hard
Dosage Strength : 20 mg/5.8 mg/15.8 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Norway
Brand Name : Teysuno
Dosage Form : Capsule, hard
Dosage Strength : 20 mg/5.8 mg/15.8 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]South Africa
Regulatory Info : Originator
Registration Country : South Africa
Brand Name : Uft
Dosage Form : CAP
Dosage Strength : 100mg
Packaging : 36X1mg
Approval Date :
Application Number :
Regulatory Info : Originator
Registration Country : South Africa
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Dossiers
Regulatory Info :
Registration Country : China
Tegafur; Gimeracil-13C3; Oteracil potassium
Brand Name :
Dosage Form : Capsule
Dosage Strength : 20MG; 5.8MG; 19.6MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Packaging :
Regulatory Info :
Tegafur; Gimeracil-13C3; Oteracil potassium
Dosage : Capsule
Dosage Strength : 20MG; 5.8MG; 19.6MG
Brand Name :
Approval Date :
Application Number :
Registration Country : China
Regulatory Info :
Registration Country : China
Tegafur; Gimeracil-13C3; Oteracil potassium
Brand Name :
Dosage Form : Capsule
Dosage Strength : 25MG; 7.25MG; 24.5MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Packaging :
Regulatory Info :
Tegafur; Gimeracil-13C3; Oteracil potassium
Dosage : Capsule
Dosage Strength : 25MG; 7.25MG; 24.5MG
Brand Name :
Approval Date :
Application Number :
Registration Country : China
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Capsules
Dosage Strength : 100; 224
Packaging : 1 x 14’s Blister (Alu-PVC)
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Packaging : 1 x 14’s Blister (Alu-PVC)
Regulatory Info :
Dosage : Capsules
Dosage Strength : 100; 224
Brand Name :
Approval Date :
Application Number :
Registration Country : India
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
